Form 4: Xenon Pharma CEO Sells Shares After Option Exercise

Xenon Pharmaceuticals' President, CEO, and Interim CFO, Ian Mortimer, sold 25,000 common shares for a weighted-average price of $40.16 after exercising options at $7.69.

Summary

• Ian Mortimer, President, CEO, and Interim CFO of Xenon Pharmaceuticals Inc. (XENE), reported a transaction involving the company's common shares.
• On October 1, 2025, Mortimer exercised options to acquire 25,000 common shares at an exercise price of $7.69 per share.
• Concurrently, on October 1, 2025, he sold 25,000 common shares at a weighted-average price of $40.16 per share.
• The sales were executed in multiple transactions with prices ranging from $40.00 to $40.495.
• These sales were made pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024.
• Following these transactions, Mortimer directly beneficially owns 31,302 common shares.
• Additionally, 14,300 common shares are indirectly beneficially owned by his spouse.

Sentiment

Score: 5

Explanation: The transaction represents a planned insider sale following option exercise, which is a common occurrence and executed under a Rule 10b5-1 plan. While it reduces direct insider holdings, it does not necessarily indicate a negative outlook on the company's future.

Positives

• The transaction demonstrates a significant profit for the insider, with shares sold at a weighted-average price of $40.16 after being acquired via options at $7.69.
• The use of a Rule 10b5-1 trading plan indicates a pre-scheduled and compliant transaction, reducing concerns about opportunistic insider trading.

Negatives

• The transaction represents a reduction in the direct beneficial ownership of common shares by a key executive (President, CEO, and Interim CFO).

Future Outlook

The filing is a transactional report and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. It reflects a specific executive's trading activity in Xenon Pharmaceuticals Inc. shares.

Corporate Governance

Related Party Transactions

• 14,300 common shares are indirectly beneficially owned by Ian Mortimer's spouse.

Stakeholder Impact

• Shareholders may interpret the sale by a key executive differently; some may view it as a normal part of compensation and liquidity planning, especially given the 10b5-1 plan, while others might perceive it as a signal of reduced confidence, despite the pre-planned nature.

Key Dates

Recommendation

The filing reports a planned insider sale by the CEO following option exercise. While insider selling can sometimes be viewed negatively, this transaction was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled and not necessarily a reflection of new negative sentiment. Without additional fundamental information, a 'hold' recommendation is appropriate as this single transaction does not fundamentally alter the investment thesis.

Keywords

Xenon Pharmaceuticals, XENE, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Ian Mortimer, CEO, Rule 10b5-1